The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...

The mid-stage IMscin002 study showed that 71% of patients preferred Tecentriq Hybreza over IV infusion. The new SC option ...

First approved by the FDA in 2016 in bladder, sales of Tecentriq are mounting, generating around $511m in 2017, and since then it has been approved lung cancer and another bladder cancer use.

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...

This means Tecentriq still needs a discount of 31%-53% from the wholesale acquisition cost list price in order for it to be considered cost effective. For Opdivo, this is 57-68%, with Keytruda ...

Citing topline data from its IMforte study, the company said Zepzelca plus Tecentriq cut mortality risk (improved overall survival) with a statistically significant effect compared to Tecentriq ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG’s ...